{"filing":{"accession_number":"0001140361-26-024556","cik":"0001453687","ticker":"RNAC","company_name":"Cartesian Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"ef20075770_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1453687/000114036126024556/ef20075770_8k.htm"},"events":[{"id":4286,"run_id":3740,"accession_number":"0001140361-26-024556","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Cartesian Therapeutics disclosed entry into a strategic licensing agreement with WestGene Biopharma for development of novel in vivo CAR-T therapies in autoimmune diseases. While this is a material partnership/licensing arrangement that could affect the company's pipeline and strategic direction, it does not fit cleanly into the M\u0026A taxonomy (which focuses on acquisitions, dispositions, mergers, or changes of control). The licensing agreement is a material collaboration event that a reasonable investor would want to know about, but lacks the acquisition/merger/control-change characteristics of ma_activity.","company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","filing_date":"2026-06-09","items":[{"id":5402,"accession_number":"0001140361-26-024556","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Cartesian Therapeutics disclosed entry into a strategic licensing agreement with WestGene Biopharma for development of novel in vivo CAR-T therapies in autoimmune diseases. While this is a material partnership/licensing arrangement that could affect the company's pipeline and strategic direction, it does not fit cleanly into the M\u0026A taxonomy (which focuses on acquisitions, dispositions, mergers, or changes of control). The licensing agreement is a material collaboration event that a reasonable investor would want to know about, but lacks the acquisition/merger/control-change characteristics of ma_activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T11:18:06.521713+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5402,"accession_number":"0001140361-26-024556","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Cartesian Therapeutics disclosed entry into a strategic licensing agreement with WestGene Biopharma for development of novel in vivo CAR-T therapies in autoimmune diseases. While this is a material partnership/licensing arrangement that could affect the company's pipeline and strategic direction, it does not fit cleanly into the M\u0026A taxonomy (which focuses on acquisitions, dispositions, mergers, or changes of control). The licensing agreement is a material collaboration event that a reasonable investor would want to know about, but lacks the acquisition/merger/control-change characteristics of ma_activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T11:18:06.521713+00:00","company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","filing_date":"2026-06-09"}]}